Clinical and Demographic Characteristics of Adult p atients with NEurofibromatosis in RUSsia

Trial Identifier: D134BR00007
Sponsor: AstraZeneca
Start Date: June 2025
Primary Completion Date: March 2028
Study Completion Date: March 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russian Federation Arkhangelsk, Russian Federation
Russian Federation Ekaterinburg, Russian Federation
Russian Federation Krasnoyarsk, Russian Federation
Russian Federation Moscow, Russian Federation
Russian Federation Saint-Petersburg, Russian Federation
Russian Federation Ufa, Russian Federation